Background Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial
lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors …

Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at
increased risk of developing lung cancer. Management of lung cancer in patients with ILD is …

Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …

Pulmonary adverse events following immune checkpoint inhibit... : Current Opinion in
Pulmonary Medicine Pulmonary adverse events following immune checkpoint inhibitors …

Patients with progressive fibrosing interstitial lung diseases (fILD) have increased morbidity
and mortality. Lung fibrosis can be associated with lung cancer. The pathogenesis of both …

Cancer patients with autoimmune disease (AID) are usually excluded from clinical trials
involving immune checkpoint inhibitors (ICIs). The available electronic databases were …

Idiopathic pulmonary fibrosis (IPF) is a globally prevalent, progressive disease with limited
treatment options and poor prognosis. Because of its irreversible disease progression, IPF …

Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC)
have pre-existing interstitial lung disease (ILD). These patients are usually excluded from …

Background Immune checkpoint inhibitors (ICIs) are widely used in cancers with or without
other treatments. Immune-related adverse events (irAEs) have been reported as side effects …

Background There is no clear consensus regarding the safety and efficacy of immune
checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) …